Intellipharmaceutics International Inc. (NASDAQ:IPCI) has been given a $6.00 target price by analysts at Maxim Group in a research report issued on Thursday. The brokerage currently has a a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 152.10% from the company’s current price.
IPCI has been the topic of a number of other reports. Brean Capital started coverage on shares of Intellipharmaceutics International in a report on Monday, October 3rd. They issued a “buy” rating and a $8.00 target price on the stock. Zacks Investment Research downgraded shares of Intellipharmaceutics International from a “buy” rating to a “hold” rating in a report on Wednesday, September 14th.
Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.38 on Thursday. The firm’s market cap is $68.42 million. The firm has a 50 day moving average of $1.95 and a 200-day moving average of $1.84. Intellipharmaceutics International has a one year low of $1.41 and a one year high of $3.19.
Intellipharmaceutics International (NASDAQ:IPCI) last released its earnings results on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Intellipharmaceutics International had a negative net margin of 325.20% and a negative return on equity of 832.00%. Equities research analysts forecast that Intellipharmaceutics International will post ($0.28) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC purchased a new position in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned approximately 0.27% of Intellipharmaceutics International as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.30% of the company’s stock.
About Intellipharmaceutics International
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.